Low 10-Year Prostate Cancer Mortality Across All Treatments: Long-Term CEASAR Data Reinforce Shared Decision-Making

A decade after diagnosis, most men with localized prostate cancer are far more likely to die of something else than of their cancer, regardless of whether they choose surgery, radiation, or active surveillance. This is the central message of the long-term follow-up from the CEASAR study, a large, prospective, observational population-based U.S. cohort that enrolled men diagnosed in 2011–2012 and followed them with contemporary treatment modalities.

The study divided patients into favourable and unfavourable prognostic groups based on clinical stage, PSA, and Grade Group, then compared prostate cancer–specific mortality, progression to advanced disease, and overall survival across treatment strategies. In the favourable-prognosis group, the 10-year cumulative incidence of dying from prostate cancer was strikingly low, no more than 1.5%, for all five management approaches, including active surveillance. Progression to metastatic or advanced disease did not differ meaningfully between surgery, external beam radiotherapy, brachytherapy, and surveillance.

Yet the same analysis found that, after adjustment for demographic and clinical covariates, external beam radiotherapy, brachytherapy, and active surveillance were each associated with higher all-cause mortality compared with surgery. This apparent survival advantage for surgery is almost certainly not a pure treatment effect. Men selected for radical prostatectomy tend to be healthier, younger, and have fewer comorbidities, and even sophisticated statistical models cannot fully erase this selection bias. The authors therefore interpret the overall survival differences as residual confounding rather than evidence that surgery extends life in low-risk disease.

In the unfavourable-prognosis stratum, external beam radiotherapy was associated with worse overall survival than surgery, with a hazard ratio near 2.8, but adjusted analyses showed no significant differences in prostate cancer–specific mortality or in progression across treatments. The unadjusted 10-year prostate cancer death rates were 3.5% after surgery and 8.8% after external beam radiotherapy, but once age, comorbidity, and other factors were accounted for, these differences were no longer statistically significant. Again, the pattern points to baseline health and treatment selection as the dominant drivers of overall survival, not a clear superiority of one modality in preventing cancer death.

These findings sit alongside other landmark data. The ProtecT randomized trial, with 15-year follow-up, showed similarly low prostate cancer mortality across active monitoring, surgery, and radiotherapy for mostly low- and intermediate-risk disease, with only modest reductions in metastatic progression for the active treatment arms. Multiple observational cohorts and meta-analyses report comparable long-term cancer-specific survival between modern surgery and radiation when patients are well matched, while consistently showing worse urinary, sexual, and bowel side-effect profiles for one approach or the other depending on the domain.

The practical upshot for clinicians and patients is that, for localized prostate cancer, the choice among surgery, radiation, and active surveillance should be driven less by the expectation of large differences in survival and more by individual values, comorbidities, life expectancy, and tolerance for specific side effects.

Source.